Bone and Soft Tissue Sarcoma
Conditions
Interventions
Sponsors
Shanghai proton and heavy ion center
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1) Patients with thoracic bone and soft tissue tumors who received particle radiotherapy at Shanghai Proton and Heavy Ion Hospital; 2) Pathologically confirmed primary thoracic bone and soft tissue tumors, or pathologically confirmed metastatic thoracic bone and soft tissue tumors from a known primary site; 3) Aged >= 14 years; 4) Having at least one follow-up visit, with the follow-up time being at least 1 month after the initiation of radiotherapy.
Exclusion criteria
Exclusion criteria: 1) At the same time, there are uncontrolled malignant tumors that may significantly shorten the expected survival of lung cancer in the patient; 2) Patients with pacemakers, such as high-energy rays that may interfere with the normal function of the pacemaker; If there is a metal prosthesis implant in the body, it may significantly affect the calculation of the target radiation dose; 3) HIV-positive, including prior treatment on antiretroviral therapy; Chronic hepatitis B, viral replication phase; active phase of hepatitis C; active syphilis; 4) have a history of psychiatric illness that may impede the completion of treatment; 5) Have serious comorbidities that may affect the delivery of radiotherapy, including: a) uncontrolled acute inflammation; b) Uncontrolled unstable angina, congestive heart failure, myocardial infarction, cerebral hemorrhage, severe chronic obstructive pulmonary disease and other cardiopulmonary and cerebral diseases, which may lead to treatment risks as assessed by specialists; c) Pregnant or lactating; d) Other diseases that may affect particle therapy; 6) the department discussed that particle radiotherapy would not be able to provide patients with a clear benefit; 7) After repeated communication, they are still unable to understand the purpose of treatment, unable to cooperate with treatment, or unwilling to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Local control rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival rate;Overall survival rate; | — |
Countries
China
Contacts
Public ContactJingfang Mao, Kai-Liang Wu
Shanghai proton and heavy ion center
Outcome results
None listed